Navigation Links
Versartis presents positive preclinical data on 2 product candidates at ENDO 09
Date:6/10/2009

Washington, DC June 10, 2009 Versartis, Inc., an emerging company developing novel biologics with enhanced properties for patients with metabolic diseases, today presented data for its long-acting product candidates, VRS-317 (hGH-rPEG) for treatment of growth hormone deficiency and for VRS-826 (IL-1ra-rPEG) for treatment of type 1 and type 2 diabetes, at the Endocrine Society's Annual Meeting in Washington, DC.

Versartis, through a unique licensing agreement with Amunix, Inc., uses the Amunix proprietary recombinant PEGylation (rPEG) technology to extend the half-life of established biologics. The preclinical Versartis compounds have the potential for significantly less frequent dosing and fewer side effects than those products currently on the market or in development.

"New half-life extension data presented today for the first time confirmed our expectation that dosing can be extended from weekly to monthly for our product candidates," said Jeffrey L. Cleland, Ph.D., Founder and Chief Executive Officer of Versartis. "Our preclinical data presented today show that VRS-317 demonstrated in vivo potency equal to daily hGH, and sustained plasma levels and pharmacodynamic responses in monkeys without toxicity. Potential benefits of VRS-317 include its stability at room temperature in a liquid formulation and the ability to dose monthly with a small gauge needle, thus increasing patient safety and convenience. VRS-317 may become 'best in class' hGH therapy when our preclinical studies are confirmed in human clinical trials."

"Treatment of auto-inflammation in diabetes with IL-1ra has been demonstrated to increase beta-cell responsiveness in human clinical trials," Dr. Cleland continued. "Our new approach with VRS-826 will provide a less frequently administered treatment that should have comparable safety to IL-1ra, which binds both IL-1b and IL-1a. The results from preclinical studies of VRS-317 and VRS-826 are being presented in poster sessions this afternoon."


'/>"/>

Contact: Debra Bannister
media@versartis.com
530-676-8001
Versartis, Inc.
Source:Eurekalert

Related biology news :

1. REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
2. Biolex presents Locteron US Phase 2a hepatitis C data at EASL
3. GSA special paper presents new studies of Western US earth motion
4. AIUM Presents 2009 Joseph H. Holmes Pioneer Awards
5. AIUM presents 2009 Memorial Hall of Fame awards
6. AIUM presents 2009 Distinguished Sonographer award
7. AIUM presents 2009 William J. Fry Memorial Lecture award
8. Stevens Center for Science Writings presents: Ravens at the Feast, with Bernd Heinrich, April 1
9. Understanding soil carbon sequestration: New book presents key concepts
10. World Congress on Osteoporosis 2010 presents outstanding scientific program
11. New manual presents robust, state-of-the-art proteomics methods for teaching and research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
(Date:3/22/2016)... , March 22, 2016 ... research report "Electronic Sensors Market for Consumer Industry by ... & Others), Application (Communication & IT, Entertainment, ... - Global Forecast to 2022", published by ... is expected to reach USD 26.76 Billion ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
Breaking Biology Technology: